AU2001270204A1 - Modulation of beta-amyloid levels by beta-secretase bace2 - Google Patents

Modulation of beta-amyloid levels by beta-secretase bace2

Info

Publication number
AU2001270204A1
AU2001270204A1 AU2001270204A AU7020401A AU2001270204A1 AU 2001270204 A1 AU2001270204 A1 AU 2001270204A1 AU 2001270204 A AU2001270204 A AU 2001270204A AU 7020401 A AU7020401 A AU 7020401A AU 2001270204 A1 AU2001270204 A1 AU 2001270204A1
Authority
AU
Australia
Prior art keywords
beta
bace2
secretase
modulation
amyloid levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001270204A
Inventor
Barbara Cordell
Yu-Wang Liu
Diana Hom Quon
Frauke Schimmoller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scios LLC
Original Assignee
Scios LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios LLC filed Critical Scios LLC
Publication of AU2001270204A1 publication Critical patent/AU2001270204A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
AU2001270204A 2000-06-28 2001-06-27 Modulation of beta-amyloid levels by beta-secretase bace2 Abandoned AU2001270204A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21572900P 2000-06-28 2000-06-28
US60/215,729 2000-06-28
PCT/US2001/020465 WO2002000913A2 (en) 2000-06-28 2001-06-27 MODULATION OF β-AMYLOID LEVELS BY β-SECRETASE BACE2

Publications (1)

Publication Number Publication Date
AU2001270204A1 true AU2001270204A1 (en) 2002-01-08

Family

ID=22804142

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001270204A Abandoned AU2001270204A1 (en) 2000-06-28 2001-06-27 Modulation of beta-amyloid levels by beta-secretase bace2

Country Status (6)

Country Link
US (3) US6713276B2 (en)
EP (2) EP1315516A2 (en)
JP (1) JP2004501652A (en)
AU (1) AU2001270204A1 (en)
CA (1) CA2413209A1 (en)
WO (1) WO2002000913A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6844148B1 (en) * 1998-09-24 2005-01-18 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
EP1196609A2 (en) 1999-06-28 2002-04-17 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
US6713276B2 (en) * 2000-06-28 2004-03-30 Scios, Inc. Modulation of Aβ levels by β-secretase BACE2
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) * 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7341991B2 (en) * 2003-12-31 2008-03-11 Posco Inhibitors of amyloid precursor protein processing
CN101142194B (en) * 2005-03-14 2012-10-10 顶点制药有限责任公司 Benzazole derivatives, compositions, and methods of use as b-secretase inhibitors
JP2009505979A (en) * 2005-08-10 2009-02-12 オクラホマ メディカル リサーチ ファンデーション Truncated memapsin 2 for use in the treatment of Alzheimer's disease
ES2537898T3 (en) 2005-10-25 2015-06-15 Shionogi & Co., Ltd. Aminothiazolidine and aminotetrahydrotiazepine derivatives as BACE 1 inhibitors
CN103301475B (en) 2005-12-28 2016-08-03 斯克里普斯研究所 Method that pharmaceutical composition and expression vector and regulator gene are expressed and the application of nucleic acid molecules
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2008073365A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
CA2672295A1 (en) * 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors containing a tricyclic ring system
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
JP5667440B2 (en) 2007-04-18 2015-02-12 プロビオドルグ エージー Thiourea derivatives as glutaminyl cyclase inhibitors
JP5383483B2 (en) * 2007-04-24 2014-01-08 塩野義製薬株式会社 Pharmaceutical composition for the treatment of Alzheimer's disease
JP5383484B2 (en) * 2007-04-24 2014-01-08 塩野義製薬株式会社 Aminodihydrothiazine derivatives substituted with cyclic groups
US9006283B2 (en) 2007-07-12 2015-04-14 Acumen Pharmaceuticals, Inc. Methods of modifying amyloid β oligomers using non-peptidic compounds
US8962677B2 (en) * 2007-07-12 2015-02-24 Acumen Pharmaceuticals, Inc. Methods of restoring cognitive ability using non-peptidic compounds
US20110098309A1 (en) * 2007-07-12 2011-04-28 Acumen Pharmaceuticals, Inc. Methods of inhibiting the formation of amyloid-beta diffusable ligands using acylhydrazide compounds
CA2707309A1 (en) 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
US20090176711A1 (en) * 2008-01-08 2009-07-09 Chi-Bom Chae Inhibitors of amyloid precursor protein processing
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
JPWO2010047372A1 (en) * 2008-10-22 2012-03-22 塩野義製薬株式会社 2-Aminopyrimidin-4-one and 2-aminopyridine derivatives having BACE1 inhibitory activity
SG171932A1 (en) * 2008-12-02 2011-07-28 Hoffmann La Roche Screening assays for the identification of bace2 inhibitors
MX2011005910A (en) 2008-12-04 2011-06-17 Opko Curna Llc Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo.
MX2012002993A (en) 2009-09-11 2012-04-19 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase.
BR112012013854A2 (en) 2009-12-11 2019-09-24 Shionogi & Co oxazine derivatives.
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
MX2012010470A (en) 2010-03-10 2012-10-09 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
WO2012057247A1 (en) 2010-10-29 2012-05-03 塩野義製薬株式会社 Fused aminodihydropyrimidine derivative
JP5816630B2 (en) 2010-10-29 2015-11-18 塩野義製薬株式会社 Naphthyridine derivatives
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2012147763A1 (en) 2011-04-26 2012-11-01 塩野義製薬株式会社 Oxazine derivative and bace 1 inhibitor containing same
JP2013158281A (en) * 2012-02-03 2013-08-19 Shionogi & Co Ltd Novel method for measuring bace1 activity
US20150031750A1 (en) 2012-03-15 2015-01-29 The Scripps Research Institute Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0647268B1 (en) 1990-06-15 2004-03-03 Scios Inc. Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
US5912410A (en) 1990-06-15 1999-06-15 Scios Inc. Transgenic non-human mice displaying the amyloid-forming pathology of alzheimer's disease
TW327194B (en) * 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same
EP0848062A3 (en) 1996-12-14 2000-07-05 Smithkline Beecham Corporation Aspartic protease ASP1
WO1999033963A1 (en) 1997-12-31 1999-07-08 Chiron Corporation Metastatic cancer regulated gene
US20030224517A1 (en) * 2002-06-04 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of beta-site APP-cleaving enzyme 2 expression
US6699671B1 (en) * 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US6844148B1 (en) * 1998-09-24 2005-01-18 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US20060101532A1 (en) * 1999-04-30 2006-05-11 Nixon Ralph A Methods for the identification of compounds for the treatment of Alzheimer's disease
US7087399B1 (en) * 1999-05-13 2006-08-08 Scios, Inc. β-secretase and modulation of β-secretase activity
PT1224297E (en) 1999-09-23 2009-08-17 Pharmacia & Upjohn Co Llc Alzheimer`s disease secretase, app substrates therefor, and uses therefor
US6713276B2 (en) * 2000-06-28 2004-03-30 Scios, Inc. Modulation of Aβ levels by β-secretase BACE2
CA2313828A1 (en) * 2000-08-01 2002-02-01 Institut De Recherches Cliniques De Montreal/Ircm Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production
AU2002243391A1 (en) * 2000-10-27 2002-06-24 The Johns Hopkins University School Of Medicine Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof
US20040203042A1 (en) * 2003-03-04 2004-10-14 Johnson Jason M Alternatively spliced isoforms of aspartyl protease 1 (BACE2)

Also Published As

Publication number Publication date
WO2002000913A9 (en) 2002-10-24
WO2002000913A2 (en) 2002-01-03
US7183070B2 (en) 2007-02-27
JP2004501652A (en) 2004-01-22
CA2413209A1 (en) 2002-01-03
US20070224656A1 (en) 2007-09-27
US20040248231A1 (en) 2004-12-09
US20020159991A1 (en) 2002-10-31
EP2359847A1 (en) 2011-08-24
US6713276B2 (en) 2004-03-30
WO2002000913A3 (en) 2003-03-13
EP1315516A2 (en) 2003-06-04

Similar Documents

Publication Publication Date Title
AU2001270204A1 (en) Modulation of beta-amyloid levels by beta-secretase bace2
AU2001294926A1 (en) Antisense modulation of smad6 expression
AU2001277054A1 (en) Antisense modulation of lysophospholipase i expression
AU2002213467A1 (en) Modulation of ccr4 function
AU2212600A (en) Antisense modulation of g-alpha-i1 expression
AU6296099A (en) Antisense modulation of g-alpha-12 expression
AU2001278077A1 (en) Antisense modulation of ptp1b expression
AU2001276934A1 (en) Methods of modulating fibrosis
AU2001294196A1 (en) Nitrogenous five-membered ring compounds
AU3561700A (en) Correction of dc-offset of i/q modulator
AU2324100A (en) Positive resist composition of chemical amplification type
AU5009200A (en) Novel beta-secretase and modulation of beta-secretase activity
AU7876900A (en) Antisense modulation of fra-1 expression
AU6109200A (en) Antisense modulation of shp-2 expression
AU2001288968A1 (en) Antisense modulation of btak expression
AU2002318139A1 (en) Antisense modulation of src-c expression
AU2209000A (en) Antisense modulation of pepck-mitochondrial expression
AU5486700A (en) Antisense modulation of g-alpha-s1 expression
AU6114100A (en) Antisense modulation of mekk1 expression
AU2001252685A1 (en) Deodorized yellow colorant of safflower
AU2410600A (en) Antisense modulation of g-alpha-i3 expression
AU2001296731A1 (en) Antisense modulation of bcas1 expression
AU2001267091A1 (en) Transdifferentiation of glial cells
AU5874800A (en) Antisense modulation of ets-2 expression
AU2001296412A1 (en) Antisense modulation of mekk4 expression